Akcea Therapeutics Inc. (NASDAQ:AKCA) does about 370.08K shares in volume on a normal day but saw 6751837 shares change hands in Monday trading. The company now has a market cap of 1.92B USD. Its current market price is $18.28, marking an increase of 60.63% compared to the previous close of $11.38. The 52 week high reached by this stock is $22.79 whilst the lowest price level in 52 weeks is $8.00. The script in recent trading has seen the stock touch a high of $19.6499 and a low of $18.15.
Akcea Therapeutics Inc. (AKCA) has a 20-day trading average at $11.79 and the current price is -19.79% off the 52-week high compared with 128.50% distance from its 52-week low. The 50-day simple moving average of the closing price is $12.58 and its 200-day simple moving average is $15.58. If we look at the stock’s price movements over the week, volatility stands at 5.92%, which decreases to 5.57% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 80.54 to suggest the stock is overbought.
5 analysts observing the Akcea Therapeutics Inc. (AKCA) stock have set the 12-month price targets for the company’s shares at between $16.00 and $41.00. The median price target is -0.72% away from the current levels at $18.15.
FactSet Research has provided data showing that 5 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 1 analysts have rated it as a buy and 4 have advised that investors hold their positions. The consensus recommendation rating is Hold and Wall Street’s advice is for investors to Moderate Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on October 07, 2019 when Wells Fargo upgraded the stock to “Outperform” and issued a price target of . Wells Fargo downgraded the stock to “Market Perform” from Outperform on September 23, 2019 at a price target of $44-$24. Needham initiated its price target at $45.
The current price level is 60.05%, 45.94%, and 17.28% away from its SMA20, SMA50, and SMA200 respectively, with the AKCA price moving below the 50-day SMA on August 31. Akcea Therapeutics Inc. (AKCA) stock is up 54.52% over the week and 68.63% over the past month. Its price is 7.91% year-to-date and -13.20% over the past year.
The stock last released its quarterly earnings report for quarter ended 6/29/2020, with the company’s earnings per share (EPS) of -$0.49 below consensus estimates by -$0.14. The company’s next earnings report is expected on 11/09/2020, with forecasts estimating quarterly EPS at -$0.44 and -$1.89 for whole year. AKCA’s earnings per share are forecast to shrink by -493.80% this year and -11.10% over next year. Expected sales for next quarter are $33.57 million, which analysts say will come at $108.14 million for the current fiscal year and next year at $161.73 million. In addition, estimates put the company’s current quarterly revenue at an average of $36.2 million.
Its 12-month price target is $18.15. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $16.00, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $41.00.
Outstanding shares total 77.10M with insiders holding 82.88% of the shares and institutional holders owning 20.84% of the company’s common stock. The company has a return on investment of 6.60% and return on equity of -8.90%. Price to book ratio is 2.94 and price to sales ratio is 5.71.
According to a U.S. Securities and Exchange Commission filing, Fidelity Growth Company Fund has reduced its position in Akcea Therapeutics Inc. (AKCA) to 4,924,693 shares, mirroring a recent drop by -0.26%. Fidelity Growth Company Fund dumped 13032.0 shares of Akcea Therapeutics Inc. common stock bringing its total worth to about $53.38 million at the end of recent close, SEC documents show. Fidelity Growth Company Fund isn’t the only investment manager who changed stakes and is followed by iShares NASDAQ Biotechnology ETF, which sold off 8140.0 shares to end up with 1,055,641 shares worth $11.44 million. Fidelity Series Growth Company Fu cut their holdings by 0.00% in the company over the course of the most recent quarter. It now holds a 1.00% position in Akcea Therapeutics Inc. thanks to 1.02 million shares amounting to $11.05 million.